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We and others have previously reported the expansion of CD5þCD19þ B cells after allogeneic hematopoietic
stem cell transplantation. Recently, the equivalent of B1 cells in mice has been described in humans as
CD20þCD27þCD43þCD70- B cells. In this article, we report that although 39% of CD5þCD19þ cells were CD43þ in
controls, >75% of CD5þCD19þ cells were CD43þ in patients independent of the presence or absence of chronic
graft-versus-host disease (GVHD) (P ¼ .0001). CD5þCD19þ B cell, CD5þCD43þCD19þ B cell, and CD27þCD43þ
B cell counts were signiﬁcantly lower in the patients with previous chronic GVHD, and this effect of GVHD was
similar in both CD5þ and CD5- within the CD27þCD43þ B cell subset. Our results strongly suggest that the
previously reported expansion of the CD5þCD19þ population might be related to an expansion of the
CD27þCD43þB cell subset and that CD27þCD43þB cell reconstitution is impaired inpatientswith chronic GVHD.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION patients with available frozen samples at 12months posttransplantation. All
Twenty-ﬁve years ago, Antin et al. [1,2] reported the early
expansion of CD5þ B cells after allogeneic hematopoietic stem
cell transplantation (HSCT) that was negatively inﬂuenced by
the occurrence of graft-versus-host disease (GVHD). Since
then, we and others have conﬁrmed those seminal ﬁndings
with the discovery of expansion of CD5þCD19þ B cells in some
autoimmune diseases and (of as-yet unknown signiﬁcance)
afterHSCT [3-6]. Recently, the equivalent of theB1 cells inmice
has been described in humans [7-9], characterized as
CD20þCD27þCD43þCD70- cells, which spontaneously secrete
IgM, efﬁciently stimulate T cells, and exhibit tonic intracellular
signaling. Of importance, 75% of B1 cells were shown to be
CD5þ in their healthy individuals. Finally, it has also been
recently reported that human B1 cells stimulate Tcells and are
expanded in lupus [10]. Despite these studies, however, the
interrelationshipsamongCD19þCD5þ cells, earlymarrowBcell
emigrants (transitional B cells), and the most recently
described B1 cell subset remain highly controversial [11,12].
Even the B1 cell phenotype described by Grifﬁn et al. [8] has
been argued [7]. Consequently, we sought to study the
CD19þCD27þCD43þ B cell subset (hereinafter termed the
“B1-like” subset) at 12 months after allogeneic HSCT.PATIENTS AND METHODS
From a previously described cohort of patients in which we studied
long-term immune reconstitution after allogeneic HSCT [4], we selected 43edgments on page 991.
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13.03.006patients had undergone allogeneic HSCT at Saint Louis Hospital in Paris
between 1995 and 2005. The selection criteria included alive without
relapse for more than 2 years after allogeneic HSCTwith available sequential
routine immune reconstitution analysis data (every 3 months during
the ﬁrst year and once per year thereafter). Patients who received a cord
blood transplantation were excluded. The median age at transplantation
was 35.7 years, and the median duration of follow-up was 70.5 months.
Patient, disease, and transplantation characteristics are summarized in
Supplemental Table 1. Written informed consent was obtained from all
patients, and the study was approved by the Medical Ethics Committee of
Saint Louis Hospital.
B, T, and NK cell subpopulations were ﬁrst enumerated in fresh whole-
blood EDTA samples by direct 4-color immunoﬂuorescence with a FACSCa-
libur ﬂow cytometer (BD Biosciences, San Jose, CA), as described previously
[4]. The analysis was performed retrospectively in peripheral blood mono-
nuclear cell (PBMC) samples stored for 12 months after HSCT. To serve as
controls, 23 samples from healthy volunteers were collected from the local
blood donor center after informed consent. All blood samples were treated
in a similar manner and processed promptly on receipt.
B lymphocyte subpopulations were labeled with the following mono-
clonal antibodies (all from BD Biosciences): CD45 PercP, CD19 PECy7, CD20
APC-Cy7, CD5 FITC, CD27 PE, and CD43 APC. Because T cell expression
of both CD27 and CD43 could complicate analysis of B1 cells owing to
B celleT cell interactions, anti-CD3 AmCyan was added.
Sample acquisition was performed with a FACSCanto II ﬂow cytometer
(BD Biosciences). Lymphocytes were examined using a double-gating
strategy, forward/side scatter, and CD45/side scatter. Doublets were dis-
criminated from single cells using Forward Side Scatter Area/Forward Side
Scatter Height gating as described previously [7-9]. B cells were subse-
quently identiﬁed as CD19þ or CD20þ and CD3- within the resulting
lymphocyte subset (Supplemental Figure 1). Results were expressed
according to ﬂuorescence minus one gating controls, allowing precise
deﬁnition of the background signal. Data were analyzed using FACSDiva (BD
Biosciences).
Datawere collected using Promise software (clinical) and Excel software
(cell phenotype). Data were divided into 2 categories: patients with chronic
GVHD and those without chronic GVHD by 12 months posttransplantation.
Mann-Whitney nonparametric tests were used to compare phenotype cell
distributions in different groups of patients. All tests were 2-sided, with the
type I error rate ﬁxed at 0.05. Statistical analyses were performed with SPSS
version 19 (IBM, Armonk, NY).
Figure 1. Relative distribution of CD5 and CD43 within CD19þ B cell subsets in controls and patients with or without chronic GVHD. (A) The proportion of CD5þ
B cells expressing CD43 is dramatically higher in patients compared with controls (76% vs 39%), regardless of the presence or absence of chronic GVHD. (Top) Gating
strategy for deﬁning CD43þ cells within the CD19þCD5þ subset. (B) CD5 distribution among B1-like cells is similar in all groups. (Top) Gating strategy for deﬁning
CD5þ cells within the B1-like subset.
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The gating strategy for studying the B1-like cell pop-
ulation and the relative proportion of B1-like cells within
the CD19þCD5þ and CD19þCD5- subsets is detailed in
Supplemental Figure 1. Staining B cells with either CD19 or
CD20 provided similar results in terms of the B1-like cell
population, as reported previously [8]. Given that our main
aimwas to study the CD19þCD5þ subset posttransplantation,
we used CD19 as a pan-B antibody. Because B1-like cells
represent a minor cell subset, and because we previously re-
ported a long-lasting defect in memory B cells (CD27þ), we
focused on 1-year B1-like cell status owing to very low
numbers in the ﬁrst 12 months posttransplantation. Our
triple-gating strategy alongwith the exclusion of CD3þ Tcells
revealed that CD19þCD43þ cells expressed low/intermediate
levels of CD43 compared with the high expression in T cells
(data not shown). This observation is in accordance with theﬁndings of Suchanek et al. [13], who recently deﬁned “puta-
tive human B1-like cells” using CD20-stringent gating to
exclude contaminating CD3þ.
Figure 1 shows the relative distribution of CD43 andCD5 in
the CD19þCD5þ and B1-like cells, respectively. Only 39% of the
CD5þCD19þ cells were CD43þ in controls, compared with
>75% in patients regardless of whether or not they had de-
veloped chronic GVHD (P ¼ .0001) (Figure 1A). Furthermore,
the proportion of B1-like cells expressing CD5 was similar in
controls and patients regardless of previous chronic GVHD
(Figure 1B). The proportion of B1-like cells staining positive
with CD5 differed in both our controls and our patients from
previously reported values, most likely related to the age of
both patients and controls, as described by Grifﬁn et al. [8].
However, our results are in accordancewith those reported by
Suchanek et al. [13], who found that a median of 11.5% of
B1-like cells expressed CD5 in their group of healthy controls.
Figure 2. CD19þCD5þ and CD19þCD5þCD43þ B cells in patients who developed chronic GVHD. (A) CD19þCD5þ (Left) and CD19þCD5þCD43þ (Right) B cell counts and
percentages are signiﬁcantly lower in patients who developed chronic GVHD before 12 months posttransplantation. (B) Similarly, B1-like cell counts are signiﬁcantly
lower in patients who developed chronic GVHD before 12 months posttranslantation. Similar results are observed whether or not CD5 is expressed on B1-like cells.
The percentage of B1-like cells within the lymphocyte population is signiﬁcantly higher in controls compared with patients.
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patients with previous chronic GVHD (P ¼ .028) (Figure 2A).
This effect was not related to a global decrease in B cell
numbers in the GVHD group, given the signiﬁcant decrease
in CD19þCD5þ percentage within total lymphocytes (P ¼ .03;
Figure 2A, Left) and CD19þ B cells (data not shown). In
addition, our data indicate that only the CD19þCD5þCD43þ
subset was signiﬁcantly decreased in patients with previous
chronic GVHD (P ¼ .024, vs P ¼ .11 in the CD19þ
CD5þCD43- subset) (Figure 2A, Right).
B1-like cell counts were also signiﬁcantly lower in the
patients with previous chronic GVHD (P ¼ .035) (Figure 2B),
although at this stage, we cannot rule out the possibility that
this is related to a global decrease in CD19þCD27þCD43þ cell
numbers (P ¼ .07 comparing B1-like cell percentage in the 2
groups). However, GVHD had the same effect on both CD5þ
and CD5- within the B1-like cell subset (Figure 2B, Right).
Taken together, our ﬁndings suggest that the previously
reported expansion of the CD5þCD19þ population might be
related to an expansion of the B1-like cell subset, and that
B1-like cell reconstitution is impaired in patients with
previous chronic GVHD.DISCUSSION
B1 cells, long described only in mice, are a small pop-
ulation of cells located principally in the peritoneum and
spleen. Several characteristics of B1 cells make them an
appealing target of study in the context of chronic GVHD;
they spontaneously secrete natural antibodies, have strong
T celleindependent activity against encapsulated bacterial
species, have strong anti-self autoreactivity, and efﬁcientlystimulate T cells [14]. B1 cells have been described in
humans only recently, however [7-10]. As noted earlier, in
the present work, we were interested in studying this
population given the known expansion of CD19þCD5þ cells
after allogeneic HSCT. Based on our ﬁndings, we suggest
that a signiﬁcant proportion of expanded B cells might be
B1-like cells, and that reconstitution of B1-like cells is
impaired in the setting of chronic GVHD. This is especially
important given the well-known susceptibility to encapsu-
lated bacterial species in patients with chronic GVHD
[6,15,16]. Considering that these cellular proportions were
measured at 12 months, after some patients had already
developed and been treated for chronic GVHD, we cannot
rule out the possibility that the treatment of GVHD itself,
rather than the disease, might have affected the number of
CD5þ B cells and B1 cells.
This study has some limitations, including the lack of
functional analysis, whichwas not possible given the amount
of frozen materials. Conﬁrmatory studies are also needed. In
addition, the biological role of CD43 expression remains to be
investigated and studied during B cell ontogeny. HSCT adds
complexity to our understanding of how the B1 cell subset
reconstitutes in this particular setting. In mice, these cells are
generated in liver and bone marrow during the fetal and
neonatal periods, and further de novo generation is due
mainly to self-renewal. Thus, the relative contribution of B1
cells from the donor and the fate of these cells after HSCT are
of interest. We have initiated a prospective longitudinal
study in HSCT recipients to investigate these issues. The
present study represents a ﬁrst step in renewing the interest
in CD19þCD5þ cells posttransplantation some 25 years after
their original description [1,2].
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Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a distinct subtype of Hodgkin lymphoma
that is characterized by unique clinical presentation, histological appearance, and indolent disease course.
The recurrent nature of disease provides an opportunity to examine the role of stem cell transplantation in its
management. We report here a single-center experience of 26 patients with relapsed NLPHL treated with
high-dose chemotherapy and autologous stem cell transplantation between 1990 and 2008. With a median
follow-up of 50 months (range, 2-138 months), the 5-year overall and event-free survival were 76% (SE 10%)
and 69% (SE 10%), respectively. Our data suggest that high-dose chemotherapy and autologous trans-
plantation should be considered as an option for patients with relapsed NLPHL.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Of the 8000 cases of Hodgkin lymphoma (HL) diagnosed in
the United States each year, 5% to 10% are further classiﬁed as
nodular lymphocyte-predominant HL (NLPHL). Descriptions
of NLPHL ﬁrst appeared in the literature in 1936, with the
extent of lymphocyte proliferation in the involved lymph
nodes suggestive of an improvement in overall survival [1]. In
